Quantcast
Home > Quotes > ARDX
ARDX

Ardelyx, Inc. Common Stock (ARDX) Quote & Summary Data

$2.57
*  
0.03
1.15%
Get ARDX Alerts
*Delayed - data as of Jul. 18, 2019  -  Find a broker to begin trading ARDX now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    ARDX After Hours
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 1.90 / $ 2.75
Today's High / Low
$ 2.61 / $ 2.50
Share Volume
87,603
50 Day Avg. Daily Volume
128,350
Previous Close
$ 2.60
52 Week High / Low
$ 4.70 / $ 1.60
Market Cap
160,883,139
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
87,603
50 Day Avg. Daily Volume:
128,350

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -1.68

Trading Range

The current last sale of $2.57 is 60.63% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 2.61 $ 4.70
 Low: $ 2.50 $ 1.60

Company Description (as filed with the SEC)

We are a biopharmaceutical company focused on developing first-in-class medicines to improve treatment choices for people with cardiorenal diseases. This includes patients with end-stage renal disease, or ESRD, suffering from elevated serum phosphorus, or hyperphosphatemia; and patients with chronic kidney disease, or CKD, and/or heart failure patients with elevated serum potassium, or hyperkalemia. Our portfolio is led by the development of tenapanor, a first-in-class inhibitor of NHE3. In our cardiorenal pipeline, tenapanor is being evaluated in a second Phase 3 clinical trial, the PHREEDOM trial, for the treatment of hyperphosphatemia in patients with ESRD who are on dialysis, with topline results expected in the fourth quarter of 2019. This trial follows a successful first Phase 3 clinical trial completed in 2017, which achieved statistical significance for the primary endpoint.  ... More ...  



Risk Grade

Where does ARDX fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 2.60
Open Date:
Jul. 18, 2019
Close Price:
$ 2.57
Close Date:
Jul. 18, 2019


Consensus Recommendation

Analyst Info